OVERVIEW
This policy documents the coverage criteria for Islet Cell Transplantation. Autologous islet transplantation, performed in conjunction with pancreatectomy, is proposed to reduce the likelihood of insulin dependent diabetes. Moreover, allogeneic islet cell transplantation is being investigated as a treatment or cure for patients with type 1 diabetes.

PRIOR AUTHORIZATION
Not applicable

POLICY STATEMENT
Autologous Islet Transplantation:
BlueCHiP for Medicare and Commercial Products
Autologous pancreas islet transplantation is considered medically necessary as an adjunct to a total or near total pancreatectomy in members with chronic pancreatitis. Islet transplantation is considered not medically necessary in all other situations as there is insufficient peer-reviewed scientific literature that demonstrates that the procedure is effective.

Allogeneic Islet Transplantation:
BlueCHiP for Medicare
Allogeneic Pancreatic islet cell transplantation is covered for BlueCHiP for Medicare members only as part of an approved clinical trial. Refer to Related Policy section.

Commercial Products
Allogeneic islet transplantation is considered not covered for the treatment of type 1 diabetes as there is no FDA approval for this indication.

MEDICAL CRITERIA
Not applicable

BACKGROUND
Pancreatectomy is utilized in the treatment of patients with chronic pancreatitis. Autologous islet transplantation, performed in conjunction with pancreatectomy, is proposed for chronic pancreatitis patients. Allogeneic islet transplantation is proposed for selected patients with type 1 diabetes.

In autologous islet transplantation, during the pancreatectomy procedure, islet cells are isolated from the resected pancreas using enzymes, and a suspension of the cells is injected into the portal vein of the patient’s liver. Once implanted, the beta cells in these islets begin to make and release insulin. In the case of allogeneic islet cell transplantation, cells are harvested from the deceased donor’s pancreas, processed, and injected into the recipient’s portal vein. Up to 3 donor pancreas transplants may be required to achieve insulin independence. Allogeneic transplantation may be performed in the radiology department.

Chronic Pancreatitis
Primary risk factors for chronic pancreatitis include toxic-metabolic, idiopathic, genetic, autoimmune, recurrent and severe acute pancreatitis, or obstructive (the TIGAR-O classification system). Patients with chronic pancreatitis may experience intractable pain that can only be relieved with a total or near total pancreatectomy. However, the pain relief must be balanced against the certainty that the patient will be rendered an insulin-dependent diabetic. Autologous islet transplantation has been investigated as a technique to prevent this serious morbidity.

**Type 1 Diabetes**

Allogeneic islet transplantation has been used for type 1 diabetes to restore normoglycemia and, ultimately, reduce or eliminate the long-term complications of diabetes such as retinopathy, neuropathy, nephropathy, and cardiovascular disease. Islet transplantation potentially offers an alternative to whole-organ pancreas transplantation. However, a limitation of islet transplantation is that 2 or more donor organs are usually required for successful transplantation, although experimentation with single-donor transplantation is occurring. A pancreas that is rejected for whole-organ transplant is typically used for islet transplantation. Therefore, islet transplantation has generally been reserved for patients with frequent and severe metabolic complications who have consistently failed to achieve control with insulin-based management.

Islet cells are subject to regulation by the U.S. Food and Drug Administration (FDA), which classifies allogeneic islet cell transplantation as somatic cell therapy, requiring premarket approval. Islet cells also meet the definition of a drug under the federal Food, Drug, and Cosmetic Act. Clinical studies to determine safety and effectiveness outcomes of allogeneic islet transplantation must be conducted under FDA investigational new drug (IND) regulation. While at least 35 IND applications have been submitted to the FDA, no center has submitted a biologics license application.

Autologous islet transplantation is proposed in conjunction with pancreatectomy for patients with chronic pancreatitis. Although the published experience with autologous islet cell transplantation is limited, the procedure appears to significantly decrease the incidence of diabetes after total or near total pancreatectomy in patients with chronic pancreatitis. In addition, this procedure is not associated with serious complications itself and is performed as an adjunct to the pancreatectomy procedure. Thus, this may be considered medically necessary.

The techniques for allogeneic islet cell transplants are evolving, and the impact on net health outcomes is still uncertain. Moreover, longer follow-up with larger numbers of patients is needed before conclusions can be drawn about the safety of allogeneic islet transplantation and its impact on diabetes mellitus and associated complications. Thus, allogeneic islet cell transplants are considered not medically necessary as there is no proven efficacy.

Guidance from the National Institute for Clinical Excellence (NICE), published in 2008, states that the evidence on allogeneic pancreatic islet cell transplantation for type 1 diabetes mellitus shows short-term efficacy with some evidence of long-term efficacy. Evidence on safety shows that serious complications may occur, and the long-term immunosuppression required is also associated with risk of adverse events. The procedure is particularly indicated for patients with hypoglycemia unawareness or those already on immunosuppressive therapy because of renal transplantation. A 2008 update of guidance on autologous islet cell transplantation for improved glycemic control after pancreatectomy states that studies show some short-term efficacy, although most patients require insulin therapy in the long term. Complications mainly result from the major surgery involved in pancreatectomy rather than from the islet cell transplantation.

Effective October 1, 2004, Medicare will cover pancreatic islet transplantation in patients with type 1 diabetes participating in the context of a clinical trial sponsored by the National Institutes of Health. Partial pancreatic tissue transplantation or islet transplantation performed outside the context of a clinical trial will continue to not be covered.
COVERAGE
Benefits may vary between groups/contracts. Please refer to the appropriate Benefit Booklet, Evidence of Coverage or Subscriber Agreement, for applicable not medically necessary/transplant surgery/experimental/investigational benefits/coverage.

CODING
BlueCHiP for Medicare and Commercial Products

The following code is covered with a diagnosis of chronic pancreatitis:

48160

The following code is reported for pancreatic islet cell transplantation and laparoscopy:

48999

ICD-10 Diagnosis Code
K86.1

RELATED POLICIES
Clinical Trials BlueCHiP for Medicare
BlueCHiP for Medicare National and Local Coverage Determinations

PUBLISHED
Provider Update January 2017
Provider Update April 2015
Provider Update November 2014
Provider Update September 2013
Provider Update September 2012
Provider Update September 2011
Provider Update December 2010
Provider Update July 2009
Provider Update June 2008

REFERENCES


This medical policy is made available to you for informational purposes only. It is not a guarantee of payment or a substitute for your medical judgment in the treatment of your patients. Benefits and eligibility are determined by the member’s subscriber agreement or member certificate and/or the employer agreement, and those documents will supersede the provisions of this medical policy. For information on member-specific benefits, call the provider call center. If you provide services to a member which are determined to not be medically necessary (or in some cases medically necessary services which are non-covered benefits), you may not charge the member for the services unless you have informed the member and they have agreed in writing in advance to continue with the treatment at their own expense. Please refer to your participation agreement(s) for the applicable provisions. This policy is current at the time of publication; however, medical practices, technology, and knowledge are constantly changing. BCBSRI reserves the right to review and revise this policy for any reason and at any time, with or without notice. Blue Cross & Blue Shield of Rhode Island is an independent licensee of the Blue Cross and Blue Shield Association.